Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prokidney (PROK) Gains from Sales and Divestitures (2022 - 2025)

Prokidney (PROK) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $959764.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Sales and Divestitures fell 28.19% to $959764.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $959764.0, a 28.19% decrease, with the full-year FY2024 number at $1.3 million, down 41.02% from a year prior.
  • Gains from Sales and Divestitures was $959764.0 for Q3 2025 at Prokidney, roughly flat from $959764.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $2.3 million in Q3 2023 to a low of $949678.0 in Q1 2025.
  • A 4-year average of $1.5 million and a median of $1.3 million in 2024 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: soared 65.89% in 2023, then crashed 41.55% in 2024.
  • Prokidney's Gains from Sales and Divestitures stood at $1.7 million in 2022, then skyrocketed by 30.67% to $2.3 million in 2023, then plummeted by 41.02% to $1.3 million in 2024, then dropped by 28.19% to $959764.0 in 2025.
  • Per Business Quant, the three most recent readings for PROK's Gains from Sales and Divestitures are $959764.0 (Q3 2025), $959764.0 (Q2 2025), and $949678.0 (Q1 2025).